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Background: Given our preclinical data showing synergy between dovitinib and paclitaxel in
preclinical models we conducted this phase I trial aiming to define the recommended
phase II-dose (RP2D) on the basis of toxicity and pharmacodynamic criteria while searching
for genetic variants that could sensitize patients to the regimen under study.
Patients and methods: A 3þ3 escalation schedule was adopted. Seriated FGF23 and dovitinib
and paclitaxel pharmacokinetic profiles were determined along a single-agent dovitinib
“priming-phase” followed by a dovitinib þ paclitaxel combination phase. RECIST 1.1
criteria and NCI CTCAE V.4.0 were used. In fresh pre-treatment tumor biopsy samples,
FGFR1, 2 and 3 amplifications were revealed by FISH probes; 32 missense variants were
genotyped in tumors and peripheral blood mononuclear cells with Taqman genotyping
assays (FGFR1-3 and RET). Constructs encoding for wild-type and variant genes associated
with clinical benefit were transfected into HEK-293 cells for preclinical experiments
checking constitutive activation and dovitinib sensitivity of the variants.
Results: twelve patients were recruited in three dose-levels. At level 1B (200 mg dovitinib 5-
days-on/2-days-off plus 60 mg/m 2-week of paclitaxel) more than 50% FGF23 upregulation
was observed and no dose-limiting-toxicities (DLTs) occurred. The most frequent toxicities
were asthenia, neutropenia, nausea/vomiting and transaminitis. Two patients with pro-
gressive disease prior to trial inclusion achieved prolonged disease stabilization. Both had
the germline variant G2071A in the RET gene, which led to constitutive activation of the
protein product and Y-905 phosphorylation, both in transfectants and in patients with the
alteration. This variant was sensitive to dovitinib; in addition both patients experienced
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dovitinib. The G2071A germline variant act as a genetic modifier that renders different tu-
mors sensitive to dovitinib.
ª 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Introduction toxicity to less than grade 2 according to the NCI CTCAE V4.0Multiple small-molecule antiangiogenics with multi-kinase
inhibitor activities have undergone clinical development.
Novel agents of this class seem to be at least as effective as
sunitinib or sorafenib, but show a better tolerability profile
(Motzer et al., 2013,2014; Rini et al., 2011). Some of these novel
agents inhibit oncogenic-addiction driving kinases on top of
pro-angiogenic kinases. Dovitinib is one of these agents,
with activity against VEGFR1-3, PDGFRA/B, FGFR1-3, KIT, RET
and FTL3 at <50 nM (Andre et al., 2013; Angevin et al., 2013;
Lee et al., 2005). Dovitinib is administered with a schedule of
5-days-on/2-days-off at a dose of 500 mg daily. Combining
an agent of this type with chemotherapy is appealing because
in monotherapy small-molecule antiangiogenics are active
against renal or liver cancer, although they show little or no
activity against the most frequent epithelial malignancies.
We demonstrated synergistic effects of combining chemo-
therapy plus dovitinib in preclinical models of pancreatic can-
cer (Hernandez-Agudo et al., 2013). In several pilot
experiments with patient-derived xenograft models we
observed additive or synergistic effects in breast, pancreas,
and lung cancer models combining dovitinib with paclitaxel
or gemcitabine, but not with adriamycin (Hernandez-Agudo
et al., 2013, and unpublished data). The wide clinical applica-
tions of weekly paclitaxel led us to choose it as the partner
for dovitinib in this trial.
Late-phase trials combining similar agents with chemo-
therapy based on the early-phase-defined RP2Ds according
to toxicity criteria suggest that long-term administration
these RP2Ds might be non-tolerable (Bergh et al., 2012; Paz-
Ares et al., 2012; Reck et al., 2010). Thus we incorporated phar-
macodynamic measurements to guide the determination of
the RP2D in case the patients showed adequate drug exposure
at non-toxic doses. Finally, because of the promiscuous activ-
ity of dovitinib against several oncogenic kinases, we deter-
mined several potential sensitizing genetic alterations that
could narrow-down the potential patient populations more
likely to benefit from dovitinib-based regimens in the future.2. Patients and methods
2.1. Patient eligibility
Patients were eligible for this phase I trial if they had a histo-
logically documented advanced solid malignancy for which
no standard therapy existed. Other eligibility criteria included:
signed informed consent; evaluable disease according to
RECIST 1.1 criteria (Eisenhauer et al., 2009); recovery to anyand adequate organ function, defined as follows (must comply
all of them): ECOG 0-2, life expectancy higher than 3 months,
adequate hematologic function (absolute neutrophil count
higher than 1500/mm3; platelet count higher than 75,000/
mm3; hemoglobin higher than 8 g/dl); serum creatinine below
1.5upper limit of normal; adequate liver function (serum
bilirubine below 1.5upper limit of normal, GOT and GPT
below 2.5upper limit of normal in presence or absence of
liver metastasis); potassium between 3 and 5.5 mmol/L and
sodium between 130 and 150 mmol/L.
Exclusion criteria included: LVEF <50%, long QTc or other
significant heart conditions; active significant endocrine con-
ditions including diabetes; and concurrent treatment with
CYP inducers or QTc-prolonging drugs.
This clinical trial was conducted in accordance with Good
Clinical Practice guidelines and was approved by the review
board and local ethics committees at eachparticipating center.2.2. Study design, dose escalation, treatment regimen
and procedures
This was a phase I, open-label dose-escalation study. A classic
3þ3 design was adopted. The treatment schedule is depicted
in Figure 1.
The starting dose (level 1) was set at 80mg/m2 of i.v. weekly
paclitaxel plus 200mg/day of dovitinib (5/2). The dose-limiting
toxicity (DLT) period assessment was from the first adminis-
tration of dovitinib to the end of the first cycle (42 days). How-
ever, no dose escalation was scheduled until all patients from
one level had completed 2 cycles of treatment (70 days).
The primary objectives of the study were to assess the
toxicity and safety of the combination, and to determine the
RP2D (based on toxicity and pharmacodynamic data) and
DLTs. The primary endpoints were frequency and severity of
adverse events and incidence of DLTs, and plasma up-
regulation of FGF23 plasma levels, a biomarker indicative of
inhibition of FGFR1 activity (Andre et al., 2013; Kim et al.,
2011). A DLT was defined as any of the following: grade 3
febrile neutropenia; grade 4 neutropenia >7 days, or grade
4 thrombocytopenia or anemia; or any non-hematologic
event more severe than non-tolerable grade 2 that required
reduction or delay beyond 1 week. The secondary objectives
were to evaluate the potential pharmacokinetic interactions
between the two agents and to preliminary evaluate the effi-
cacy of the combination depending on genetic alterations of
the targets of dovitinib. The secondary endpointswere disease
response, progression-free survival and determination of mu-
tations/amplifications of FGFR1-2-3 and RET. Dovitinib in-
hibits FGFR1-2-3, RET, and other targets (VEGFR1-3, PDGFRA/
Figure 1 e Treatment schedule. The screening included conventional assessments plus an image-guided tumor biopsy (within 7 days before to the
first dovitinib dose) and LVEF determination. Dovitinib was then administered orally for a week (“priming phase”); a pharmacokinetic profile was
obtained on an inpatient basis on day 1. Blood samples for pharmacodynamic determinations were obtained at 0 and D24 h. After a 1 week “wash-
out” period, the treatment phase started with concurrent treatment of dovitinib D paclitaxel. A second pharmacokinetic profile (so that the
paclitaxel-induced modifications in dovitinib pharmacokinetics could be studied) including as well paclitaxel determinations, in order to compare
the pharmacokinetics in combination with dovitinib with historical data of weekly paclitaxel (Fennelly et al., 1997), and two additional samples for
pharmacodynamic determinations were obtained. The patients were discharged after 24 h and the treatment was continued with dovitinib
administered orally on a schedule of 5-days-on/2-days-off in combination with weekly paclitaxel, in 28-days cycles. Patients were visited and
evaluated for toxicity weekly beginning with the first dose of dovitinib and until the end of the first cycle, bi-weekly during the second and third
cycles, and subsequently on a monthly basis. RECIST evaluations were performed every 2 cycles.
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reasons: first, FTL3 and PDGFRB, and PDGFRB and CKIT, are
mostly known to be mutated and related with sensitivity to
other inhibitors in hematologic malignancies (Heinrich et al.,
2008a) and GISTs (Heinrich et al., 2008b). The target population
to be included in the CNIO-BR-002 trial was non-hematologic
tumors, and the likelihood of including GIST patients due to
competitive trials in this malignancy, very low. Second,
VEGFR1-3 mutations and SNPs have been widely studied as
potential biomarkers for antiangiogenics, mostly with nega-
tive results with the exception of some SNPs (Garcia-Donas
et al., 2011). However, recent findings from several TCGH
studies, pointed towards FGFR1-2-3 and RET as potential
novel, yet unexplored, oncogenic addiction drivers. All the ge-
netic variants tested were assayed both in tumor tissue and
peripheral blood mononuclear samples in order to determine
their germline or somatic origin.
2.3. Pharmacokinetic sampling; pharmacodynamic and
genetic determinations and correlative studies with wild-
type and mutant-RET variants
Fasted dovitinib alone (day 1 of the priming phase) or in com-
bination with 1-h infusion of paclitaxel (day 1 of the combina-
tion phase) pharmacokinetics were determined by using avalidated liquid chromatography with tandem mass spec-
trometry method with a lower limit of quantification
(LLOQ) of 1.0 ng/mL. Plasma paclitaxel concentrations were
determined by using a validated high-performance liquid
chromatography method with a LLOQ of 5.0 ng/mL. Noncom-
partmental pharmacokinetic analysis was conducted using
the Phoenix software (Pharsight Inc., Mountain View, CA) to
determine key pharmacokinetic parameters including Area
Under the concentration-time Curve (AUC) and themaximum
plasma concentration of dovitinib (Cmax).
Free FGF23 was determined by using the FGF23-ELISA Kit
from Millipore, following manufacturer’s instructions.
Tumor biopsy samples were obtained within 7 days before
to treatment start and snap-frozen in liquid nitrogen in OCT-
blocks. Amplifications in the FGFR1/2 and FGFR3 loci were
determined with probes from Kreatech and Zytolight, respec-
tively, by counting the signal over>200 interphasic nuclei and
setting a cut-off threshold of 2.
The 32missense substitutions in FGFR1, 2, 3 and RET genes,
gathered in Table 1, were determined with Taqman SNP gen-
otyping assays (Life Technologies), using the primers-probes
sequences offered in Supplementary Table 1. They were
collected from COSMIC (http://cancer.sanger.ac.uk/cancerge-
nome/projects/cosmic/) and dbSNP (http://www.ncbi.nlm.-
nih.gov/SNP/) databases, and were selected based on their









FGFR1 c.374C > T p.S125L rs121913473 COSM601 NA 1 1 NA
c.754C > A p.P252T rs121913472 COSM12834 NA 1 1 NA
c.755C > G p.P252R rs121909627 NA NA 1 NA pathogenic
FGFR2 c.755C > G p.S252W rs79184941 COSM36903 NA 3 48 pathogenic
c.1647T > A p.N549K rs121913476 COSM36912 NA 1 20 NA
c.1144T > C p.C382R rs121913474 COSM36906 NA 1 9 NA
c.758C > G p.P253R rs77543610 COSM49170 NA 2 7 pathogenic
c.870G > C p.W290C rs121918499 COSM41286 NA 1 3 pathogenic
c.929A > G p.K310R rs121913475 COSM36901 NA 1 2 NA
c.1124A > G p.Y375C rs121913478 COSM36904 NA 2 8 pathogenic
FGFR3 c.746C > G p.S249C rs121913483 COSM715 NA 1 1243 pathogenic
c.1118A > G p.Y373C rs121913485 COSM718 NA 1 407 pathogenic
c.742C > T p.R248C rs121913482 COSM714 NA 1 240 pathogenic
c.1108G > T p.G370C rs121913479 COSM716 NA 1 114 pathogenic
c.1111A > T p.S371C rs121913484 COSM17461 NA 1 56 pathogenic
c.2089G > T p.G697C rs121913480 COSM24802 NA 1 44 NA
c.1948A > C p.K650Q rs78311289 COSM726 NA 2 5 pathogenic
c.1948A > G p.K650E rs78311289 COSM719 NA 0 46 pathogenic
c.1949A > C p.K650T rs78311289 COSM731 NA 0 5 pathogenic
c.1949A > T p.K650M rs78311289 COSM720 NA 0 36 pathogenic
c.1950G > T p.K650N rs78311289 COSM1428730 NA 5 1 pathogenic
c.1172C > A p.A391E rs28931615 COSM721 NA 3 32 pathogenic
c.749C > G p.P250R rs4647924 NA NA 4 NA pathogenic
c.1138G > A p.G380R rs28931614 COSM24842 NA 2 12 pathogenic
c.1620C > G p.N540K rs28933068 NA NA 3 NA pathogenic
RET c.2753T > C p.M918T rs74799832 COSM965 NA 3 290 pathogenic
c.1900T > C p.C634R rs75076352 COSM966 NA 5 12 pathogenic
c.1901G > A p.C634Y rs75996173 COSM974 NA 7 7 pathogenic
c.1902C > G p.C634W rs77709286 COSM975 NA 3 5 pathogenic
c.2304G > C p.E768D rs78014899 COSM21338 NA 2 4 pathogenic
c.2071G > A p.G691S rs1799939 COSM1666596 0.155 22 1 Benign
c.2944C > T p.R982C rs17158558 NA 0.017 14 0 other
All variants were tested both in tumor and germline material.
NA: Non available.
MAF: Minor allele frequency.
dbSNP (mut) and COSMIC (mut) columns report on the number of reported samples with the variant (may/2014).
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edge about these genes available back in 2011, when the study
was designed and the Taqman SNP genotyping assays pre-
pared. The known variants in 2011 are depicted in
Supplementary Table 2. Those variants with the highest fre-
quency were selected, after excluding synonymous-coding
variants.
Thirty micrograms of total protein from tumor areas with
>90% epithelial content weremixed with Laemmly buffer, de-
natured and separated by 7.5 SDS-PAGE and transferred onto
nitrocellulose membranes. Membranes were incubated with
antibodies for RET and phospho-tyrosine 905-RET (both from
Cell Signaling Technology, #3223 and #3221 respectively) and
solved with a conventional chemoluminescence detection
system.
Regarding the experiments with wild type andmutant RET
variants, the methods were as follows:
The pWZL-Neo-RET from Addgene (20614) was used to ex-
press the RET mutant containing the A substitution in codon
691 (AGT). The RETwild type constructwas generated by using
the QuikChange II Site-Directed Mutagenesis Kit (Stratagene,La Jolla, CA) according to the manufacturer’s protocol. Briefly,
PCR reaction was carried out with 10 ng of template vector,
125 ng of each primer, 200 uM dNTPs, and 2.5 U pfue Turbo
DNA polymerase using the following cycling
conditions:1 min at 95 C, 18 cycles of 50 s at 95 C, 50 s at
60 C and 13 min at 68 C, followed by 7 min at 68 C. After
PCR reaction plasmid were amplified in XL10-Gold ultracom-
petent cells (Strategene) and substitution was confirmed by
DNA sequencing.
Primers containing the AeG substitution in codon 691 (AGT




HEK-293 cell line used for this study was grown in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS; Sigma). HEK-293 cells were
plated at a density of 0.5  106 cells/p100-mm-diameter
plates overnight in DMEM-10% FBS. Transfection was per-
formed after 24 h with 5 ug of the indicated plasmids conju-
gated to 0.5 uL Lipofectamine 2000 (Invitrogen) in Opti-
Table 2 e Baseline demographics and patient characteristicsa.
Characteristic Value
Age (median; range) 62.5 (37.9e73.4)
Sex (male/female) 7 (64%)/4 (36%)
ECOG (0/1) 3 (27%)/8 (73%)
Baseline FEV1 (median; range) 69.2 (55e75)
Tumor type
- Lung 1 (9%)
- Breast 1 (9%)
- Pancreas 1 (9%)
- Uterine carcinosarcoma 1 (9%)
- Adenoid cystic carcinoma 1 (9%)
- Epithelioid hemangioendothelioma 1 (9%)
- Colorectal 5 (46%)
- Prior number of systemic
regimens for metastatic disease
(median; range)
4 (1e9)
- Patients with prior antiangiogenic
treatment
7 (64%)
a One patient withdrew consent prior to receiving the first treat-
ment dose. Eleven patients are evaluable for toxicity and efficacy.
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with Neoymycin was started 48 h after transfection, and
maintained until clones were observed (4 weeks approxi-
mately). More than 10 clones were picked and successfully
expanded both for wild-type and variant RET stable transfec-
tants. Three different clones per genotype were routinely
tested for experimental purposes; representative data are
shown.
Stable clones (wild type or variants) were exposed for
2 h to 250 nM of dovitinib or vehicle. The cells were washed
with PBS and scraped into a tube containing washing buffer
(150 mM NaCl, 50 mM HEPES, protease and phosphatase In-
hibitor Cocktail (Thermo Scientific, Rockford, IL), vortexed
and centrifuged at 12,000 rcf at 4 C, 2 min. The supernatants
were discarded. Pellets were resuspended in lysis buffer (Cell
Signaling Technology, Beverly, MA), homogenized, sonicated
for 15 min at 4 C, centrifuged and supernatant collected.
Protein concentration was measured for each sample by
with a BSA protein kit (Pierce, Rockford, IL) and spectropho-
tometry. Equal amounts of total protein (30 mg) were mixed
with Laemmli buffer, denatured, and separated by 7.5%
SDS-PAGE and then transferred on nitrocellulose membra-
nas (Bio-Rad Laboratories, Mississauga, Ontario, Canada)
following the manufacturer’s instructions. Non-specific
binding sites were blocked for 1 h with Tris buffered saline
(TBS))-Tween 1%e5% of Bovine Serum Albumin (BSA) (Sig-
maeAldrich) at RT. Membranes were incubated with anti-
bodies for RET (C31B4clone) (1:1000; Cell Signaling
Technology, Beverly, MA) and phospho-RET (1:1000; Cell
Signaling Technology, Beverly, MA). Tubulin was detected
using a monoclonal antibody against g-tubulin (1:5000; Sig-
maeAldrich, Oakville, Ontario, Canada). After overning incu-
bation at 4 C, blots were rinsed with Tris buffered saline
(TBS)-Tween 1% and then incubated with goat anti-rabbit
horseradish peroxidase-linked immunoglobulin G (IgG) or
goat anti-mouse horseradish peroxidase-linked IgG for 1 h
at RT. After rinsing, immunoreactive bands were visualizedwith an enhanced chemiluminescence detection system
(ECL, Amersham International, Cardiff, UK).
2.4. Statistics
The safety analysis population comprised all patients who
received one or more doses of study drugs. Because of the
number of patients enrolled in the trial, the analyseswere per-
formed with descriptive statistics.3. Results
Between April 18, 2012 and April 15, 2013, 12 patients were
registered. Patient characteristics are summarized in Table 2.
3.1. Dose escalation, DLTs, adverse events and drug
exposure
One patient enrolled in level 1 (with colorectal cancer meta-
static to brain and lungs) experienced G4 neutropenia plus
G2 non-tolerable mucositis on day þ50. The patient was
admitted to the hospital. On day 6 the patient presented respi-
ratory insufficiency; the chest X-ray showed diffuse intersti-
tial infiltrate and the patient died 24 h later. Definitive
classification of this event [(nosocomial infection secondary
to the neutropenia vs disease progression (lymphangitic carci-
nomatosis)] was not possible. The other two patients did not
experience severe toxicity. Because of the possibly-related
G5 event, although outside the DLT-period, the dose-level
was expanded. The fourth patient experienced a DLT (G3
asthenia þ diarrhea plus G4 GGT elevation). The protocol
was stopped for safety reasons and amended with new dose
levels.
Recruitment re-started at level 1B (60 mg/m2 of weekly
paclitaxel plus 200 mg/day of dovitinib 5/2); no DLTs were
registered (3 patients). The first two patients enrolled at level
2B (60 mg/m2 of weekly paclitaxel plus 300 mg/day of doviti-
nib) did not experience DLTs; the third, experienced G3
asthenia; therefore a fourth patient was enrolled. However,
the first patient at level was found dead at his home, 10 weeks
after starting treatment and right before disease re-evaluation
(no autopsy was performed). At that point, the sponsor
applied to the Spanish Drug Agency for early study closure
on the grounds of safety reasons and study termination was
mandated. All the patients still receiving medication stopped
participation in the trial despite lack of significant toxicity.
Twenty-seven priming-phases and 27 cycles were admin-
istered. The toxic events per level and number of cycles are
depicted in Table 3. No meaningful toxicities occurred during
the priming phase. The median relative dose intensities were
97% for dovitinib and 76% for paclitaxel. At dose level 1B, the
relative dose intensity was >97% for both drugs.
3.2. Pharmacokinetics and pharmacodynamics
Dovitinib pharmacokinetic parameters in the absence and in
the presence of paclitaxel are provided in Figure 2. Detailed
parameters for both agents are included in Table 4. An in-
crease in dovitinib pharmacokinetic parameters can be
Table 3 e Toxicity per cycle and level occurring in at least 10% of the cycles (excluding alopecia).
Level, toxicity type Grade 1e2 (%) Grade 3 (%) Grade 4 (%) Grade 5a (%)
Level 1 (5 cycles administered)
Diarrhea 40% 20% e e
Mucositis 40% 20% e e
Asthenia 80% 20% e e
Lymphopenia e 40% e e
Neutropenia 40% 20% 40% e
Thrombopenia 20% 20% e e
Hypophosphatemia 40% 40% e e
Nausea/vomiting 60% e e e
ALT elevation 20% e e e
AST elevation 60% e e e
GGT elevation 40% e 20% e
Hypoalbuminemia 80%
Hypomagnesemia 40% e e e
Cough 20% e e e
Level 1B (14 cycles administered)
Diarrhea 50% e e e
Mucositis 7% e e e
Asthenia 86% e e e
Lymphopenia 28% e e e
Neutropenia 21% e e e
Thrombopenia 14% e e e
Hypophosphatemia 14% e e e
Nausea/vomiting 65% e e e
ALT elevation 21% e e e
AST elevation e e e e
GGT elevation e e 57%b e
Hypoalbuminemia e e 14% e
Hypomagnesemia 14% e e e
Peripheral neuropathy 57% e e e
Cough 36% e e e
Hypoproteinemia 36% e e e
Onycolysis 36% e e e
Peripheral edema 36% e e e
Rash 29% e e e
Taste alterations 21% e e e
Level 2B (8 cycles administered)
Diarrhea 62% e e e
Mucositis e e e e
Asthenia 75% 12% e e
Lymphopenia 37% 12% e e
Neutropenia 12% e e e
Hypophosphatemia 25% e e e
Nausea/vomiting 25% e e e
FA elevation 75% 25% e e
ALT elevation 50% e e e
AST elevation 62% e e e
GGT elevation 75% 12% 12% e
Hypoalbuminemia 12% 12% e e
Peripheral neuropathy 25% e e e
Cough 12% e e e
Hypoproteinemia 37% e e e
Onycolysis 12% e e e
Peripheral edema 25% e e e
Rash 25% e e e
Taste alterations 50% e e e
Phlebitis e 25% e e
Lipase elevation 12% e e e
a The two grade 5 events cannot be related or ruled out definitively to be disease progression or grade 5 infection (patient in level 1), or disease
progression or grade 5 bleeding (patient in level 2B).
b One patient presented elevated GGT for 8 cycles and since the beginning; the patient entered protocol with a waiver form.
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Figure 2 e Pharmacokinetics and pharmacodynamics. (A) Dovitinib
plasma concentration-time profiles in the presence (solid-line with
squars) and absence (dotted-line with triangles) of paclitaxel. (B)
Average plasmatic FGF23 levels per timepoint (baseline, 24 h after
the first dovitinib dose, before the first dovitinib dose of the
combination phase and 24 h later) and dose levels. Error bars:
standard error of the mean.
Table 4 e Dovitinib pharmacokinetic parameters in the presence







Cmax (ng/mL) 135  52 186  94
AUC (h.ng/mL) 2590  1137 3167  1875
Paclitaxel PK:
Cmax (ng/mL) NA 556  271
AUC (h.ng/mL) NA 3441  235
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the literature for single-agent weekly paclitaxel, suggesting
adequate exposure to the cytotoxic agent (Fennelly et al.,
1997; Ready et al., 2007). The FGF23 plasma concentration
time course per dose level followed the kinetics depicted in
Figure 2B. Increases in FGF23 plasma concentration of 50%e
100% have been correlated with reduced pERK in tumors and
clinical activity in previous trials, despite different schedules
(Andre et al., 2013; Kim et al., 2011), suggesting adequate
average pharmacodynamic effect at all tested levels.
3.3. Selective activity over G2071A RET-activating
germline genetic variant
No patient tested positive for either amplification of FGFR1, 2
or 3, or 31 of the 32 genetic variants in the FGFR genes or
RET-genes. Two patients with epithelioid hemangioendothe-
lioma and adenoid cystic carcinoma, respectively, were found
to harbor a G-to-A coding variant in the 2071 position of the
RET gene (exon 11), leading to a glycine to serine change in po-
sition 691 (Figure 3A). The variant was of germline origin, as
we confirmed the G-to-A change in peripheral-bloodmononu-
clear cells in both patients. This variant is predicted togenerate two novel serine phosphorylation sites in the RET
protein, and to possibly enhance its kinase activity (Lantieri
et al., 2013). This variant is associated with earlier onset in
sporadic medullary thyroid carcinoma (Robledo et al., 2003),
it is aggregated in patients with sporadic medullary thyroid
carcinoma (Elisei et al., 2004) and it is frequently found in des-
moplastic melanoma (Narita et al., 2009). In vitro studies have
shown that this variant is associated with increased onco-
genic signaling and cell replication/invasion (Sawai et al.,
2005). Although meta-analyses do not suggest its role as a he-
reditary cancer gene, these reports suggest that it functions as
a genetic modifier or even a low-penetrance gene.
We transfected HEK293 cells with plasmids encoding wild-
type and G2071A variants and tested the phosphorylation
levels of 905-Y-RET, the site that translates “active” conforma-
tional state.We found that the G2071A variant shows>10-fold
higher phosphorylation rates in this tyrosine site, whereas in
resting conditions, the phosphorylation of the wild-type
variant is negligible (Figure 3B). Interestingly, this constitu-
tively active variant was sensitive to dovitinib (Figure 3B).
HEK293 cells did not express endogenous RET levels, what
avoids potential confounding factors (Figure S1A); the effects
of dovitinib in non-transfected or empty-vector-transfected
HEK293 are provided in Figure S1B.
The two patients with the genetic variant had constitutive
905-Y-RET phosphorylation (Figure 3C). Both patients were
experiencing disease progression that was documented by
two consecutive CT scans performed within 3 months before
enrollment. Once they received trial medication, both
achieved disease control. One had disease control for more
than 9 months and discontinued the trial because of cumula-
tive toxicity deemed related to paclitaxel. The other patient
discontinued the trial because of the sponsor’s decision to
close the trial; this patient was without toxicity or progression
at 4 months after registration. Both patients experienced dis-
ease progression after medication withdrawal. Thus, the pro-
gressive disease was controlled by the medication in the
patients harboring the dovitinib-sensitive, RET-hyperacti-
vated variant, and this control was lost uponmedicationwith-
drawal, suggesting a causeeeffect relationship between
dovitinib exposure and disease control in these two cases.3.4. Disease control in the remainder patients
At the time of trial report, 6 (55%) patients had died; five of
them died because of disease progression (one during
Figure 3 e Activating RET variant sensitive to dovitinib. (A) Electropherogram showing the wild-type sequence (G, left panel) and the variant
sequence (A, right panel) in the 2071 position. (B) HEK-293 cells were transfected with a wild-type or a mutant-RET-encoding plasmid and
blotted for anti-905-Y-RET, in the presence and in the absence of dovitinib. It can be appreciated how the baseline levels of RET phosphorylation
are highly increased in the mutant variant, despite similar total RET levels, whereas it is completely sensitive to dovitinib exposure. Virtually no
residual phosphorylation of RET remains after incubation with 250 nM of dovitinib (2 h). (C) Western blot of anti-905-Y-RET performed with
lysates from tumor biopsy sample (only 5 biopsy samples yielded sufficient tissue after performing the FISH and mutational analysis). The two
patients showing therapeutic benefit are those with the RET genetic variant, showing baseline increased phosphorylation. The numbers above the
bands indicate how long (in months) the disease was controlled.
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Therewere no tumor responses. Four patients were not evalu-
able. One of these four was not evaluable because of early trial
closure, one because of toxicity and two because of exitus
before to the first scheduled evaluation.
Out of the 7 evaluable patients, 5 (71%) presented disease
progression as best response. The other two patients were
the patientswith the active RET-variant. Thus, no disease con-
trol was achieved in absence of this variant. Themedian over-
all survival and progression-free survival (including the
patients with the variant) were 6 months (95% C.I.: 2.7e9.7)
and 2.7 months (95% C.I.: 2.2e3.4), respectively. Best response,
PFS and OS at the individual level are provided in
Supplementary Table 3.4. Discussion
Dovitinib is a multikinase inhibitor agent with activity against
angiogenic and tumor stromal regulators and several onco-
genic kinases.
Agentsof this classusually face twochallenges foradequate
development in solid malignancies: first, besides the case of
liverandkidneycancer, they requirecombinationwithchemo-
therapy forbeingeffective inmostepithelial cancers.However,
these combinations are often toxic in the long term. Long-term
administration at the single-agent RP2D is substantially toxic,
as recently reported in the randomized phase III trial of renal
cell carcinomapatientswithone-thirdof thepatients requiring
dose reductions and approximately half of the patients
requiring dose interruptions (Motzer et al., 2013,2014). Patientsusually are administered medications for longer periods in
phase III than in phase I trials; this is a common problem
with multi-kinase inhibitors. Long-term toxicity is an even
more severe issue inchemotherapyplusmulti-kinase inhibitor
trials (Bergh et al., 2012; Paz-Ares et al., 2012; Reck et al., 2010).
However, patients might be adequately exposed to both drugs
with doses below the maximum tolerated dose, what can be
determined by pharmacodynamic parameters. Thus, we
designed this trialwithapharmacodynamicendpoint, because
it was possible that the patients were adequately exposed to
dovitinib at doses less than the maximum-tolerated doses.
The second challenge is that targetedagents are unlike to exert
their activity in unselected patient populations; thus, it is
appealing to find easy-to-determine markers that narrow-
down patients subgroupswhere activity ismore likely to occur
e for this reason, we assessed the status of genetic variants of
dovitinib targets with high probability of functional implica-
tions (missense variants with possible function enhancer
properties).
The examination of the PK data (Figure 2, Table 4) shows an
almost 40% increase in the dovitinib concentration at 24 h,
>40% increase in the Cmax and almost 25% increase in the
AUC, when administered in combination with paclitaxel
compared with in monotherapy. However, the small number
of patients led to large standard errors that complicate the
data interpretation. The paclitaxel exposure in this study
(Table 4) was within the ranged of exposure observed in the
literature (Fennelly et al., 1997; Ready et al., 2007). Among
the side effects that determined DLTs probably only transami-
nitis can be unequivocally attributed to dovitinib. At this dose
level, previous studies have not shown high incidence of
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monotherapy. Potentially, plasmatic accumulation of doviti-
nib attributable to the combination could account for this.
Regarding neutropenia, the effects of dovitinib on FTL3, a re-
ceptor involved in normal myeloid maturation, might
enhance the otherwise mild myelosuppressor effects of the
administered paclitaxel doses. Interestingly, we showed
adequate pharmacodynamic modulation in the three dose
levels (Figure 2B), with similar fold-increments of FGF23 as
those reported in the literature (Andre et al., 2013; Kim et al.,
2011). The pharmacodynamic effects plus the pharmacoki-
netic data suggesting accumulation of dovitinib makes us
believe that the exposure to the targeted agent at level 1B is
sufficient. Together with the lack of toxicity at this level, we
recommend it as the RP2D. Although the early trial closure
because of sponsor decision did not allow us to, it would
have been interesting to further explore this dose level by
including more patients. However, this is currently a limita-
tion of our study because of the actions taken.
A second point of importance in the era of targeted ther-
apies is finding biomarkers that can narrow-down potential
patients populations more likely to benefit from a given
drug. Germline genetic variations, although associated
with less penetrant phenotypes, are easier and cheaper to
determine. Germline and somatic RET variants have been
implicated mostly in endocrine malignancies. Here we
report for the first time the potential role of a germline
variant in RET as a potential biomarker of activity for a tar-
geted therapy. This variant caused an aminoacid change in
position 691 that was hypothesized to lead to increased RET-
kinase activity (Lantieri et al., 2013). Here, we show that
such is actually the case, as evidenced by the striking in-
crease in constitutive tyrosine phosphorylation in position
905 (Figure 3B). This variant has not been associated with
MEN syndromes or with hereditary endocrine cancers,
although the gain-of-function effects in the protein are
evident in the literature in preclinical and epidemiologic
studies (Elisei et al., 2004; Narita et al., 2009; Robledo et al.,
2003; Sawai et al., 2005). The gain of function is probably
insufficient to transform, but it may act as an enhancer.
Although not a bonafide oncogene, the minor-allele-
frequency of this variant is between 15 and 20%; conversely,
oncogenic variants are usually highly sensitizing to targeted
therapies but their incidence is usually low. Like oncogenic
variants, this gain-of-function variant is sensitive to doviti-
nib according to our preclinical data (Figure 3B). Regarding
the clinical data, 2/11 patients enrolled in this trial had
this germline genetic variant present. Interestingly,
although RET has not been implicated yet in the biology of
epithelioid hemangioendothelioma or adenoid cystic carci-
noma, we show how both cases had increased RET activa-
tion (Figure 3C), what could render these patients sensitive
to dovitinib. Both patients had progressive disease before
entering the trial and were the only two patients showing
signs of activity, suggesting that this is a sensitizing poly-
morphism. A retrospective study involving archival samples
from a recently completed randomized trial with dovitinib is
currently ongoing, and should clarify this point, in order to
justify, or not, prospective interventional studies in
G2071A genetically-enriched patient cohorts.Funding
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